EP0467337B1 - Conservation des essais diagnostiques - Google Patents

Conservation des essais diagnostiques Download PDF

Info

Publication number
EP0467337B1
EP0467337B1 EP91111961A EP91111961A EP0467337B1 EP 0467337 B1 EP0467337 B1 EP 0467337B1 EP 91111961 A EP91111961 A EP 91111961A EP 91111961 A EP91111961 A EP 91111961A EP 0467337 B1 EP0467337 B1 EP 0467337B1
Authority
EP
European Patent Office
Prior art keywords
isothiazolin
hydrochloride
methyl
chloroacetamide
imidazolidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91111961A
Other languages
German (de)
English (en)
Other versions
EP0467337A3 (en
EP0467337A2 (fr
Inventor
Gerhard Dr. Rer. Nat. Hoss
Dr. Rer. Nat. Pappert
Axel Dr. Rer. Nat. Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Publication of EP0467337A2 publication Critical patent/EP0467337A2/fr
Publication of EP0467337A3 publication Critical patent/EP0467337A3/de
Application granted granted Critical
Publication of EP0467337B1 publication Critical patent/EP0467337B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/24—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms
    • A01N43/26—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings
    • A01N43/28—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings with two hetero atoms in positions 1,3
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A01N47/36—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< containing the group >N—CO—N< directly attached to at least one heterocyclic ring; Thio analogues thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/963—Methods of stopping an enzyme reaction or stabilizing the test materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/826—Additives, e.g. buffers, diluents, preservatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2525—Stabilizing or preserving

Definitions

  • the invention relates to the preservation of diagnostic tests, in particular test kits by means of a combination of preservatives, and diagnostic tests containing such agents.
  • Biological, in particular diagnostic, test kits usually contain, as reagents and as standards, substances which can be decomposed by microorganisms. To improve their durability, they must therefore be preserved by the manufacturer.
  • suitable preservatives for such diagnostics, since in addition to being sufficiently effective against bacteria, yeasts and fungi, the reactivity of substances present in the test must not be disturbed by the preservative used.
  • the sensitivity of proteins such as Enzymes or antibodies as well as antigens and substrates to preservatives are shown e.g. that the proteins can be denatured or that immunogenic structures are destroyed.
  • added preservatives often bind such substances and thus compete with the actual binding partner in the test (e.g. binding enzyme / substrate, antibody / antigen). So far, it has therefore been necessary to find a suitable preservative for each specific diagnostic test that has the aforementioned properties.
  • EP-A-0 067 394 discloses an aqueous cholesterol standard solution which contains a detergent mixture and optionally additionally suitable preservatives such as azide, germal or chloroacetamide and a buffer.
  • the aim of the invention is to provide preservatives which can be used very generally in diagnostic tests, which cover a large spectrum of germs in their preservative properties and which minimize the formation of resistant germs. In this way, the testing and storage of preservatives should be limited to a few substances and the search for new preservatives that have the properties described above should be reduced or eliminated altogether.
  • This object is achieved by a combination of preservatives which are particularly suitable for preserving diagnostic tests and which contain at least two components selected from the group consisting of 2-methyl-4-isothiazolin-3-one hydrochloride, 2 Hydroxypyridine-N-oxide, chloroacetamide, (N, N-methylene-bis (N- (1-hydroxymethyl) -2,5-dioxo-4-imidazolidinyl)) urea and 5-bromo-5-nitro-1, 3-dioxane, with the exception of the combination of chloroacetamide with (N, N-methylene-bis (N-1-hydroxymethyl) -2,5-dioxo-4-imidazolidinyl)) urea.
  • preservatives which are particularly suitable for preserving diagnostic tests and which contain at least two components selected from the group consisting of 2-methyl-4-isothiazolin-3-one hydrochloride, 2 Hydroxypyridine-N-oxide, chloroacetamide, (N, N-m
  • 2-methyl-4-isothiazolin-3-one hydrochloride in combination with at least one of the aforementioned preservatives.
  • Preservatives which are 2-methyl-4-isothiazolin-3-one hydrochloride and 2-hydroxypyridine-N-oxide or 2-methyl-4-isothiazolin-3-one hydrochloride and chloroacetamide or 2-methyl are therefore particularly preferred -4-isothiazolin-3-one hydrochloride and N, N-methylene-bis (N- (1-hydroxymethyl) -2,5-dioxo-4-imidazolidinyl)) urea or 2-methyl-4-isothiazolin-3 -on hydrochloride and 5-bromo-5-nitro-1,3-dioxane.
  • 2-Methyl-4-isothiazolin-3-one hydrochloride (hereinafter also referred to as methylisothiazoline) can be obtained by the methods described by SN Lewis et al., J. Heterocycl. Chem. (1971), 8 , 571 and in U.S. Patent 4,105,431 (1968).
  • 2-Hydroxypyridine-N-oxide is sold as a 20% solution under the name Oxy-pyrion by Pyrion-Chemie, Neuss, Federal Republic of Germany and can be isolated from it by extraction with ethyl acetate and / or chloroform and subsequent removal of the extractant by distillation .
  • N N-methylene-bis- (N- (1-hydroxymethyl) -2,5-dioxo-4-imidazolidinyl)
  • urea is sold under the trade name Germall 115 by Chemag AG, Frankfurt, Federal Republic of Germany.
  • 2-chloroacetamide is available from E. Merck, Darmstadt, Federal Republic of Germany.
  • 5-bromo-5-nitro-1,3-dioxane is sold by Henkel KG, Federal Republic of Germany, under the trade name BRONIDOX.
  • the invention therefore also relates to diagnostic tests, in particular diagnostic test kits, which contain, as preservatives, a combination of at least two substances selected from the group consisting of 2-methyl-4-isothiazolin-3-one hydrochloride, 2-hydroxypyridine-N-oxide, chloroacetamide and (N, N-methylene-bis (N- (1-hydroxymethyl) -2,5-dioxo-4-imidazolidinyl)) urea and 5-bromo-5-nitro-1,3-dioxane.
  • 2-methyl-4-isothiazolin-3-one hydrochloride in an amount of 0.001 to 0.5%, 2-hydroxy-pyridine-N-oxide, chloroacetamide and (N, N-methylene-bis - (N- (1-hydroxymethyl) -2,5-dioxo-4-imidazolidinyl)) - urea in an amount of 0.1 to 0.5% and 5-bromo-5-nitro-1,3-dioxane in contain an amount of 0.001% to 0.5%, based on the concentration in the aqueous solution in which the test kit or the standards or buffer solutions are stored until they are used.
  • the preservative combination according to the invention can be added to both the buffer and the respective test reagent in the test kit. However, it has also proven expedient to add the preservative combination to the test reagents and the buffer solutions at the same time.
  • the test reagents in the test kits according to the invention are usually biologically active proteins and in particular enzymes and / or antibodies.
  • the invention also relates to the use of the preservative combination according to the invention for preserving diagnostic tests.
  • the preservative combination according to the invention has proven to be very particularly suitable for tests which contain proteins, in particular enzymes, antibodies and / or protein hormones, substrates for such enzymes, hormones, in particular T 3 , T 4 or steroids and / or antigens or Haptens included.
  • the mixture thus contains approximately 10 5 CFU / ml, the proportion of Bacillus subtilis being approximately 10 3 CFU / ml.
  • the storage temperature of the batch is 31 ° C.
  • the number of colonies in batches A and B is determined.
  • samples of 0.5 - 2 ml are taken from the batches and diluted in 2 parallel dilution series with physiological saline, in accordance with the expected germ titer, and the colony number is determined by plating out on nutrient agar plates.
  • Each 0.1 ml is distributed manually or using a spiral plate device on standard agar plates (90 mm ⁇ ). The dilution depends on the colony count to be expected.
  • Table 1 The results are shown in Table 1.
  • the values in the table indicate the number by which the germs are reduced by adding the preservative after the storage period of 6 weeks.
  • the respective order numbers given in the table indicate the order numbers of Boehringer Mannheim GmbH, Federal Republic of Germany.
  • Preservation is sufficient if the requirements in section 5 are met. In this case, it is to be expected that the protective effect of the preservation is sufficient against contamination that occurs when filling under unsterile conditions or when these reagents are handled normally (airborne germs, hand-held germs, non-sterile pipettes, non-sterile packaging materials).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Claims (10)

  1. Combinaison pour la conservation de trousses de tests diagnostiques, caractérisée par une teneur en au moins deux constituants choisis dans le groupe comprenant le chlorhydrate de 2-méthyl-4-isothiazolin-3-one, le 2-hydroxypyridine-N-oxyde, le chloracétamide, la (N,N-méthylène-bis(N-(1-hydroxyméthyl)-2,5-dioxo-4-imidazolidinyl))-urée et le 5-bromo-5-nitro-1,3-dioxane, à l'exception de la combinaison du chloracétamide avec la (N,N-méthylène-bis(N-(1-hydroxyméthyl)-2,5-dioxo-4-imidazolidinyl))-urée.
  2. Combinaison selon la revendication 1, caractérisée en ce qu'elle contient du chlorhydrate de 2-méthyl-4-isothiazolin-3-one.
  3. Trousse de test diagnostique conservée, comprenant des réactifs de test et au moins deux agents de conservation choisis dans le groupe comprenant le chlorhydrate de 2-méthyl-4-isothiazolin-3-one, le 2-hydroxypyridine-N-oxyde, le chloracétamide, la (N,N-méthylène-bis(N-(1-hydroxyméthyl)-2,5-dioxo-4-imidazolidinyl))-urée et le 5-bromo-5-nitro-1,3-dioxane.
  4. Trousse de test selon la revendication 3, caractérisée en ce qu'elle contient du chlorhydrate de 2-méthyl-4-isothiazolin-3-one.
  5. Trousse de test selon la revendication 3 ou 4, caractérisée en ce qu'elle contient du chlorhydrate de 2-méthyl-4-isothiazolin-3-one en une concentration efficace de 0,001 à 0,5%.
  6. Trousse de test selon les revendications 3 à 5, caractérisée en ce qu'elle contient du 2-hydroxypyridine-N-oxyde en une concentration efficace de 0,1 à 0,5%.
  7. Trousse de test selon les revendications 3 à 6, caractérisée en ce qu'elle contient du chloracétamide en une concentration efficace de 0,1 à 0,5%.
  8. Trousse de test selon les revendications 3 à 7, caractérisée en ce qu'elle contient de la (N,N-méthylène-bis(N-(1-hydroxyméthyl)-2,5-dioxo-4-imidazolidinyl)-urée en une concentration efficace de 0,1 à 0,5%.
  9. Trousse de test selon les revendications 3 à 7, caractérisée en ce qu'elle contient du 5-bromo-5-nitro-1,3-dioxane en une concentration efficace de 0,001 à 0,5%.
  10. Utilisation de la combinaison d'agents de conservation selon la revendication 1 ou 2 pour la conservation de trousses de tests diagnostiques.
EP91111961A 1990-07-18 1991-07-17 Conservation des essais diagnostiques Expired - Lifetime EP0467337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022878A DE4022878A1 (de) 1990-07-18 1990-07-18 Konservierung von diagnostischen tests
DE4022878 1990-07-18

Publications (3)

Publication Number Publication Date
EP0467337A2 EP0467337A2 (fr) 1992-01-22
EP0467337A3 EP0467337A3 (en) 1993-01-13
EP0467337B1 true EP0467337B1 (fr) 1997-06-04

Family

ID=6410541

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91111961A Expired - Lifetime EP0467337B1 (fr) 1990-07-18 1991-07-17 Conservation des essais diagnostiques

Country Status (8)

Country Link
US (1) US5300424A (fr)
EP (1) EP0467337B1 (fr)
JP (1) JPH0778005B2 (fr)
AT (1) ATE153831T1 (fr)
DE (2) DE4022878A1 (fr)
DK (1) DK0467337T3 (fr)
ES (1) ES2104636T3 (fr)
GR (1) GR3023855T3 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460797A (en) * 1991-05-08 1995-10-24 Streck Laboratories, Inc. Method for fixing tissues and cells for analysis using oxazolidine compounds
US5849517A (en) * 1991-05-08 1998-12-15 Streck Laboratories, Inc. Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
DE4344549A1 (de) * 1993-12-24 1995-06-29 Boehringer Mannheim Gmbh Konservierung von Säulenmaterialien in wässrigen Lösungen
DE4422374A1 (de) * 1994-06-27 1996-01-04 Boehringer Mannheim Gmbh Konservierungsmittelmischung für diagnostische Testflüssigkeiten
US5667983A (en) * 1994-10-24 1997-09-16 Chiron Diagnostics Corporation Reagents with enhanced performance in clinical diagnostic systems
US5512213A (en) * 1995-03-01 1996-04-30 Betz Laboratories, Inc. Aqueous stabilized isothiazolone blends
US5935857A (en) * 1997-08-01 1999-08-10 Coulter International Corp. Blood diluent
US20080064108A1 (en) * 1997-12-10 2008-03-13 Tony Baker Urine Preservation System
US7569342B2 (en) * 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
US6927062B2 (en) * 2002-11-25 2005-08-09 Agdia, Inc. Controls and standards for assays and method for manufacture thereof
JP4959959B2 (ja) * 2005-07-22 2012-06-27 株式会社タイショーテクノス 水性工業製品の防腐防黴方法および防腐防黴剤組成物
JP2007031299A (ja) * 2005-07-22 2007-02-08 Taisho Technos Co Ltd 工業用防腐防黴剤組成物
EP2415461B1 (fr) 2010-07-24 2012-10-31 Roche Diagnostics GmbH Stabilisation d'interleukine 6 dans des solutions à base de sérum
CN112314593A (zh) * 2020-11-03 2021-02-05 武汉尚飞生物科技有限公司 一种适用于病毒样本常温保存的保存液及其制备方法
CN113897413A (zh) * 2021-10-12 2022-01-07 广州达安基因股份有限公司 一种体外诊断试剂防腐剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452034A (en) * 1967-03-09 1969-06-24 American Cyanamid Co Substituted 2-(1,3,4-thiadiazol-2-yl)-4(5)-nitroimidazoles
US4040977A (en) * 1973-10-16 1977-08-09 Sterling Drug Inc. Preservative and disinfectant
IL50858A (en) * 1976-03-26 1979-07-25 Coulter Electronics Stabilized hematological reagent solutions comprising 2-phenoxy-ethanol and an alkali metal fluoride
US4279993A (en) * 1979-11-13 1981-07-21 Magers Thomas A Indicator composition and test device containing amine oxide, and method of use
DE3122917A1 (de) * 1981-06-10 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Waessrige cholesterin-standardloesung und verfahren zu ihrer herstellung
DE3303098A1 (de) * 1983-01-31 1984-08-02 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und reagenz zur glucosebestimmung im haemolysierten blut
FR2598514B1 (fr) * 1986-05-12 1988-07-01 Commissariat Energie Atomique Procede de dosage immunologique des hormones thyroidiennes t3 et/ou t4 utilisant la thyroglobuline
US4964892A (en) * 1988-12-22 1990-10-23 Rohm And Haas Company Synergistic microbicidal combinations containing 2-N-octyl-3-isothiazolone and certain commercial biocides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 108, no. 21, 23. Mai 1988, Columbus, Ohio, US; M Terajima. Seite 378 *
EP 194466 *
EP 398795 *

Also Published As

Publication number Publication date
US5300424A (en) 1994-04-05
DK0467337T3 (da) 1997-12-22
ES2104636T3 (es) 1997-10-16
EP0467337A3 (en) 1993-01-13
GR3023855T3 (en) 1997-09-30
ATE153831T1 (de) 1997-06-15
JPH04243804A (ja) 1992-08-31
JPH0778005B2 (ja) 1995-08-23
EP0467337A2 (fr) 1992-01-22
DE59108734D1 (de) 1997-07-10
DE4022878A1 (de) 1992-01-23

Similar Documents

Publication Publication Date Title
EP0467337B1 (fr) Conservation des essais diagnostiques
DE69705126T2 (de) Zusammenwetzungen und verfahren zur entgiftung von zearalenon
DE69127888T2 (de) Konservierungslösung für Zellen
DE69919196T2 (de) Verfahren zum screening von antibakteriellen mitteln
DE69624593T2 (de) Verfahren zum nachweis von bakterien
DE60035156T2 (de) Eine Zusammensetzung zur Bereitstellung von dauerhaft haltbaren Zellen für diagnostische Tests
DE19922538A1 (de) Flüssig-Konzentrat zur Konservierung von Kosmetika
DE69521128T2 (de) Synergistische, wasserlösliche konservierungsmittelzusammensetzungen von bioziden mischungen
DE69333586T2 (de) Verfahren und zusammensetzung zur konservierung von antigenen und verfahren zur verwendung von durch selbiges verfahren hergestellten zytologischem material
DE102010054155A1 (de) Verwendung von aliphatischen Alkoholen bei der Herstellung eines Desinfektionsmittels zur Verhinderung der Verunreinigung des Desinfektionsmittels mit bakteriellen Sporen
US4025620A (en) Treatment of canine otitis and composition therefor
DE69123848T2 (de) Stabile sauerstoff-freie reagenzienlösung für diagnostik
DE69114457T2 (de) Sehr rasche feststellung von pilz-infektionen.
EP0734525B1 (fr) Procede utilisant des proteines vegetales transporteuses pour l&#39;identification de substances ayant un effet potentiel herbicide ou regulateur de croissance
DE2728456A1 (de) Verfahren zur feststellung pathogener mikroorganismen in den menschlichen atemwegen
DE2554587C2 (de) Desinfektionsmittel
DE4313408A1 (de) Cyclodextrin-Biocid-Komplex
EP0068438A2 (fr) Moyens et méthode pour la détection du peroxyde d&#39;hydrogène
DE69504960T2 (de) Hemmung der proteaseaktivität von lysaten aus menschlichen vollblut
EP0119990A2 (fr) Procédé de préparation de dérivés de plasma thérapeutiquement administrables, conditionnés dans des emballages prêts à l&#39;emploi
Engler et al. Die Bildung der infektiösen Ribonucleinsäure während der Vermehrung des Tabakmosaikvirus
Müller Die Erregerdiagnostik der systemischen Pilzerkrankungen mit besonderer Berücksichtigung quantitativer Methoden (Part 1 of 2)
DE60118409T2 (de) Herstellungsverfahren von immunglobulinen, die gegen menschliche thymozyten gerichtet sind
DE947827C (de) Verfahren zur Konservierung zersetzlicher Stoffe
EP0302011B1 (fr) Anticorps monoclonaux et procédé pour le diagnostic d&#39;infections par phyrophtora

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910717

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950502

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 153831

Country of ref document: AT

Date of ref document: 19970615

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19970606

REF Corresponds to:

Ref document number: 59108734

Country of ref document: DE

Date of ref document: 19970710

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3023855

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2104636

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20000705

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20000710

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20000712

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20000918

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010717

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20010731

Year of fee payment: 11

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

BERE Be: lapsed

Owner name: BOEHRINGER MANNHEIM G.M.B.H.

Effective date: 20010731

EUG Se: european patent has lapsed

Ref document number: 91111961.8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030206

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20070620

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20070619

Year of fee payment: 17

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: BOEHRINGER MANNHEIM GMBH

Free format text: BOEHRINGER MANNHEIM GMBH# #68298 MANNHEIM (DE) -TRANSFER TO- BOEHRINGER MANNHEIM GMBH# #68298 MANNHEIM (DE)

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20090201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20090706

Year of fee payment: 19

Ref country code: FR

Payment date: 20090708

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090612

Year of fee payment: 19

Ref country code: CH

Payment date: 20090811

Year of fee payment: 19

Ref country code: DE

Payment date: 20090730

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20090731

Year of fee payment: 19

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100717

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110201

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 59108734

Country of ref document: DE

Effective date: 20110201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100717

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100717

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100718